Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Fecal Microbiota Transplant Feasibility Study in Alzheimer's Disease
NCT03998423Phase 1Terminated
- Sponsor
- University of Wisconsin–Madison
- Start
- Nov 2019
- Primary completion
- Jul 2020
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 1, open-label trial of fecal microbiome transplant in Alzheimer's disease (AD) (3 arms), sponsored by University of Wisconsin–Madison. Primary endpoints: Adverse Events at 1 year, Participant recruitment rate at 1 year and 4 more. Started Nov 2019; status: terminated.
02
Drugs
fecal microbiome transplant
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT03998423.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03998423.